The one thing that I will looking at straight away with this quarterly will be the table below!!!
If we have got numbers like the last quarter ($64,000) for revenue then I will have lost all faith in the companies ability to sign a license / contract that will get us all rich!
From all of the announcements leading up to the launches of Vivagel products for BV, we were led to believe that we were entering into a ~$1b market with a product that is safer and more effective than existing products.......
There is either one or two things going on here:
1. The company has failed to sign a license with a company that will effectively market the product and achieve real market penetration which translates into $'s
OR
2. SPL oversold the potential of the Vivagel product to the market and us poor gullible investors.....
COVID cannot be used as an excuse for poor revenues coming from Vivagel.
SPL Price at posting:
$1.52 Sentiment: Hold Disclosure: Held
